Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 7, 2008

Varian Pays $37M for Oxford Diffraction

  • Varian has taken ownership of Oxford Diffraction  for approximately $37 million in cash and assumed net debt. Oxford is a privately owned company based in Abingdon, U.K., that is focused on x-ray crystallography.

    The transaction also includes an opportunity for additional purchase price payments over three years, dependent on future financial performance. Those future payments could total up to $10 million if aggressive performance targets are achieved. Oxford Diffraction generated revenues of approximately $15 million for the twelve months ended March 31, 2008.

    "The acquisition of Oxford Diffraction is key to Varian's goal of broadening its range of information-rich detection products for life science research," says Garry W. Rogerson, president and CEO at Varian.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »